CNS Pharmaceuticals Inc. CNSP Archives - Page 8 of 22

WednesdayDec 14, 2022 10:30 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Anchors Focus and Priority on Berubicin Clinical Development for GBM Treatment

John Climaco, CNS’s CEO, has lauded the company’s progress in Q3 2022, noting the successful expansion of its pivotal Berubicin trial into Europe within the quarter The company hopes to address the unmet need associated with GBM treatment with its lead drug candidate, Berubicin, trusting that the expansion into Europe will be integral to achieving interim analysis by mid-2023 CNS looks to build on the successful patient enrollment and dosing in France, which brings its operational tally to 29 of 68 clinical sites enrolling patients across the United States and Europe, as it works toward interim analysis of clinical trials…

MondayDec 12, 2022 10:30 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Has Potential to Make History in Battle Against Deadly Brain Cancer with Berubicin

Glioblastoma, also known as GBM, is a fatal and incurable brain cancer that tends to recur aggressively after initial treatment CNS Pharmaceuticals is a U.S.-based pharmaceutical innovator whose flagship drug candidate, Berubicin, is a potentially pivotal treatment for treating GBM because of its novel apparent ability to cross the blood-brain barrier at effective levels CNS is building upon prior clinical trial outcomes with its global potentially pivotal trial currently registering patients in the United States and Europe Berubicin’s development is being advanced with potential time and cost savings thanks to the FDA’s decision to grant it Fast Track and Orphan…

ThursdayDec 08, 2022 11:45 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Preliminary Results from Berubicin Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has released data from its ongoing trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”). The data was presented at the annual meeting for the Society for Neuro-Oncology. Those results indicate that enrolled patients have comparable demographics, including age, gender, race, BSA and KPS; in addition, the percentage of patients continuing on study or having withdrawn is comparable between arms. “Although data are still early, we are pleased with these results in terms of…

MondayDec 05, 2022 10:46 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate in ‘Ask the CEO’ Event

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its Chief Executive Officer John Climaco will participate in the Virtual Investor “Ask the CEO” event. The live, moderated event is intended to provide the investment community direct access to ask their questions to Climaco on Tuesday, Dec. 6, at 11:00 a.m. ET. As part of the virtual event, Climaco will provide a brief presentation, followed by an interactive question-and-answer session. Questions can be submitted live during the event or pre-submitted…

ThursdayDec 01, 2022 11:56 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Pricing for Public Offering

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced the pricing of a public offering. The offering is comprised of 1,889,764 shares of common stock (or prefunded warrants in lieu thereof) along with warrants to purchase up to 1,889,764 shares of common stock at a combined public offering price of $3.175 per share and associated warrant. The company noted that common warrants will be immediately exercisable at $3.03 per share and will expire five years following the initial exercise date. According to the announcement, the…

TuesdayNov 29, 2022 10:00 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) 1-for-30 Reverse Stock Split Now in Place

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has announced a 1-for-30 reverse split of its common stock. According to the announcement, the split was effective at 4:01 p.m. ET on Nov. 28, 2022. Starting today, CNSP common stock will trade on the Nasdaq Capital Market on a split-adjusted basis a new CUSIP number: 18978H201. Approved by company stockholders earlier this year, the reverse stock split is meant to increase the CNSP’s per share trading price and bring the company into compliance with the…

MondayNov 28, 2022 9:00 am

European Clinical Trial Site Expansion for CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Brain Cancer Drug Candidate Drives Patient Enrollment

U.S.-based drug innovator CNS Pharmaceuticals is continuing to advance its global human clinical trial for Berubicin, a potentially pivotal treatment for the incurable brain cancer glioblastoma CNS recently announced its Q3 financial results, including an update on the clinical development that noted the start of patient enrollment and dosing in France CNS is also advancing trial sites in the United States, Switzerland, Spain, and Italy, with 29 of 68 anticipated sites currently enrolling patients The company expects to provide an interim analysis of the trials in mid-2023 and primary completion in 2024, with ultimate resolution in 2025 The FDA has…

WednesdayNov 23, 2022 3:05 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Seeking to Solve Unmet Need for GBM Treatment

CNS Pharmaceuticals (NASDAQ: CNSP) is an oncology drug development company specializing in developing anti-cancer drugs for the treatment of primary and metastatic brain and central nervous system cancer. “The first half of fiscal 2022 saw the company make a number of clinical and operational advancements in its pursuit of treatment for glioblastoma multiforme (‘GBM’), according to CNS Pharmaceuticals CEO John Climaco. The company’s focus and priorities, Climaco emphasized, are firmly anchored in the advancement of its clinical development for its drug candidate Berubicin with the aim of bringing meaningful treatment to GBM patients. And as he separately told attendees at…

TuesdayNov 22, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Announces First European Dosing in Potentially Pivotal GBM Trial

The National Brain Tumor Society anticipates that more than 13,000 Americans will receive a GBM diagnosis during 2022, accounting for 49.1% of all primary malignant brain tumors CNS announced the first patient in Europe has been enrolled and dosed in the global trial to evaluate Berubicin for the treatment of GBM Berubicin is a novel anthracycline and the first to appear to cross the blood-brain barrier The global GBM treatment market is expected to reach a value of $4.2 billion by 2028, driven by the increased approval granted by the FDA for novel GBM treatment therapies CNS Pharmaceuticals (NASDAQ: CNSP),…

WednesdayNov 16, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) CEO Participated in The American Brain Tumor Association’s Breakthrough for Brain Tumors(R) 5K Run Following European Clinical Trial Site Activations

CNS Pharmaceuticals CEO John Climaco participated in 5K run on November 5, to show support for brain tumor patients worldwide and help raise funds for research The company recently announced European clinical trial site activations for its potentially pivotal global trial evaluating Berubicin for the treatment of recurring glioblastoma multiforme The pivotal trial will study Berubicin’s results compared to the current study of care, Lomustine Global brain tumor treatment market was valued at $2,946 million in 2022 and is expected to grow to $5,904 million by 2032 Brain and other central nervous system cancers (“CNS”) represent 1.3% of all new…

Site Search

Company Search

Tag: CNS Pharmaceuticals Inc. CNSP